Central Aortic Pressure and Arterial Stiffness in Parkinson's Disease: A Comparative Study.
Journal
Parkinson's disease
ISSN: 2090-8083
Titre abrégé: Parkinsons Dis
Pays: United States
ID NLM: 101539877
Informations de publication
Date de publication:
2022
2022
Historique:
received:
17
05
2021
revised:
06
05
2022
accepted:
27
06
2022
entrez:
22
7
2022
pubmed:
23
7
2022
medline:
23
7
2022
Statut:
epublish
Résumé
Cardiovascular autonomic dysfunction, which leads to hemodynamic disorders, is commonly observed in patients with Parkinson's disease (PD). Central aortic pressure (CAP) is the systolic blood pressure (SBP) at the root of the aorta. In young people, CAP is lower than peripheral arterial blood pressure. In older people, the difference between CAP and peripheral arterial blood pressure decreases depending on the extent of arterial stiffness (AS). In patients with AS, CAP increases. CAP is thus regarded as an indicator of AS. To compare CAP and other hemodynamic parameters for AS between patients with Parkinson's disease and control group. We also aimed to evaluate changes in these hemodynamic parameters after the levodopa (LD) intake. We included 82 patients with PD and 76 healthy controls. Age, sex, disease duration, disease subtype, Hoehn-Yahr stage (H&Y), and nonmotor symptoms (NMS) were documented. TensioMed Software v.3.0.0.1 was used to measure CAP, peripheral arterial blood pressure, pulse pressure (PP), heart rate (HR), mean arterial pressure (MAP), augmentation index (AI), pulse wave velocity, and ejection time. All patients were being treated with LD, and measurements were performed 1 h before and 1 h after LD intake. Baseline peripheral arterial blood pressure and CAP values were significantly higher in the PD group than in the control group ( Loss of postganglionic noradrenergic innervation is well-known with PD. Several cardiac hemodynamic parameters were affected, suggesting cardiac autonomic dysfunction in these patients. The data obtained were independent of disease severity, duration, and subtype. After LD intake, most of these parameters decreased, which might have a positive effect on the vascular burden.
Sections du résumé
Background
UNASSIGNED
Cardiovascular autonomic dysfunction, which leads to hemodynamic disorders, is commonly observed in patients with Parkinson's disease (PD). Central aortic pressure (CAP) is the systolic blood pressure (SBP) at the root of the aorta. In young people, CAP is lower than peripheral arterial blood pressure. In older people, the difference between CAP and peripheral arterial blood pressure decreases depending on the extent of arterial stiffness (AS). In patients with AS, CAP increases. CAP is thus regarded as an indicator of AS.
Objective
UNASSIGNED
To compare CAP and other hemodynamic parameters for AS between patients with Parkinson's disease and control group. We also aimed to evaluate changes in these hemodynamic parameters after the levodopa (LD) intake.
Methods
UNASSIGNED
We included 82 patients with PD and 76 healthy controls. Age, sex, disease duration, disease subtype, Hoehn-Yahr stage (H&Y), and nonmotor symptoms (NMS) were documented. TensioMed Software v.3.0.0.1 was used to measure CAP, peripheral arterial blood pressure, pulse pressure (PP), heart rate (HR), mean arterial pressure (MAP), augmentation index (AI), pulse wave velocity, and ejection time. All patients were being treated with LD, and measurements were performed 1 h before and 1 h after LD intake.
Results
UNASSIGNED
Baseline peripheral arterial blood pressure and CAP values were significantly higher in the PD group than in the control group (
Conclusion
UNASSIGNED
Loss of postganglionic noradrenergic innervation is well-known with PD. Several cardiac hemodynamic parameters were affected, suggesting cardiac autonomic dysfunction in these patients. The data obtained were independent of disease severity, duration, and subtype. After LD intake, most of these parameters decreased, which might have a positive effect on the vascular burden.
Identifiants
pubmed: 35864933
doi: 10.1155/2022/6723950
pmc: PMC9296341
doi:
Types de publication
Journal Article
Langues
eng
Pagination
6723950Informations de copyright
Copyright © 2022 Mehmet Balal et al.
Déclaration de conflit d'intérêts
The authors declare that they have no conflicts of interest.
Références
Brain Pathol. 2005 Jan;15(1):29-34
pubmed: 15779234
Circulation. 2006 Mar 7;113(9):1213-25
pubmed: 16476843
Am J Hypertens. 2002 May;15(5):453-8
pubmed: 12022248
Heart. 2012 Mar;98(6):490-4
pubmed: 22194150
Parkinsonism Relat Disord. 2008 Dec;14(8):600-7
pubmed: 18325818
J Pers Med. 2021 Feb 15;11(2):
pubmed: 33671878
Lancet Neurol. 2003 Nov;2(11):669-76
pubmed: 14572735
Neurol Sci. 2013 Apr;34(4):557-60
pubmed: 22893360
J Mov Disord. 2017 Sep;10(3):135-139
pubmed: 28851210
Parkinsonism Relat Disord. 2014 Aug;20(8):815-8
pubmed: 24819390
J Am Soc Hypertens. 2014 Mar;8(3):152-8
pubmed: 24629400
J Neural Transm (Vienna). 2014 Oct;121(10):1259-68
pubmed: 24692006
Hypertens Res. 2002 May;25(3):359-64
pubmed: 12135313
J Neurol Neurosurg Psychiatry. 2002 Dec;73(6):776-7
pubmed: 12438492
J Mov Disord. 2016 May;9(2):97-103
pubmed: 27020456
Molecules. 2021 Mar 10;26(6):
pubmed: 33802165
Hypertension. 2005 Apr;45(4):575-9
pubmed: 15767471
J Neurol Sci. 2011 Nov 15;310(1-2):118-22
pubmed: 21529844
N Engl J Med. 1997 Mar 6;336(10):696-702
pubmed: 9041100
Circ J. 2010 Nov;74(11):2257-62
pubmed: 20962429
Age Ageing. 2007 Jan;36(1):43-8
pubmed: 17114200
Neurobiol Dis. 2012 Jun;46(3):572-80
pubmed: 22094370
Clin Cardiol. 2012 Jan;35(1):26-31
pubmed: 22083664
Neurodegener Dis. 2017;17(2-3):89-96
pubmed: 27784025
Mol Med Rep. 2012 Dec;6(6):1337-42
pubmed: 23023866
Mov Disord. 2007 May 15;22(7):1004-8
pubmed: 17427942
Ann Nucl Med. 2013 Jun;27(5):444-51
pubmed: 23443954
Klin Wochenschr. 1985 Nov 4;63(21):1117-23
pubmed: 4079278
Clin Auton Res. 2012 Feb;22(1):57-61
pubmed: 21796351
Circ J. 2010 Jan;74(1):24-33
pubmed: 19920359
J Neural Transm (Vienna). 2015 Oct;122(10):1441-6
pubmed: 25797035